Search Results
Your search for Blood matches 4666 pages
Showing 2901 - 2950New Antiviral Agent May Prevent Posttransplant Cytomegalovirus Infections
Patients receiving the antiviral letermovir (MK-8228, AIC246), as compared to placebo, were almost twice as likely to avoid infection with cytomegalovirus or fail for other reasons in a randomized phase III international trial presented at the 2017 BMT Tandem Meetings, the joint meeting of the...
Thoracic 2017: Genetic Profile of Treatment-Resistant Lung Cancer More Variable Than Previously Thought
The genetic mutations underlying treatment resistance in non–small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who acquired resistance to epidermal growth factor receptor (EGFR) inhibitors, the most common form...
Thoracic 2017: Biomarker Test Shows Cancer Recurrence Months Before CT Scans
Results from a prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of 6 months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating...
Association of DNA Thioguanine Nucleotide Concentration and Outcome During Maintenance Therapy for Childhood ALL
In a substudy of a European phase III trial (Nordic Society of Pediatric Hematology and Oncology ALL2008) reported in The Lancet Oncology, Nygaard Nielsen et al found that higher leukocyte DNA-incorporated thioguanine nucleotide (DNA-TGN) levels were associated with an improved relapse-free...
ASCO Honors Researchers and Scientists for Significant Advancements in Cancer Treatment and Care
ASCO and the Conquer Cancer Foundation of ASCO (CCF) have proudly announced the winners of ASCO's Special Awards, the Society's highest honors, and the CCF Women Who Conquer Cancer Mentorship Award. The recipients of these awards include researchers, patient advocates, and global oncology leaders...
UK Trial Shows No Survival Benefit in Adding Pravastatin to Standard Chemotherapy in Small Cell Lung Cancer
In the UK phase III LUNGSTAR study reported in the Journal of Clinical Oncology, Seckl et al found that adding pravastatin to first-line standard chemotherapy did not improve overall survival in patients with small cell lung cancer (SCLC). Numerous large prospective cohort and registry studies...
Ibrutinib in Marginal Zone Lymphoma
On January 19, ibrutinib (Imbruvica) was granted accelerated approved for treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20–based therapy.1 Supporting Efficacy Data Approval was based on overall response rate in a...
Novel Immunotherapy Added to Standard Care Did Not Meet Endpoint in Patients With Advanced Head and Neck Cancer
In the phase II Active8 trial, a novel immunotherapy agent, motolimod, failed to improve outcomes over chemotherapy plus cetuximab (Erbitux) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In a post hoc analysis, however, patients with injection-site...
Close to Home: Dr. Rick Boulay’s Experience With Cancer Survivorship and Caregiving
Richard ‘Rick’ Boulay, MDChief of Gynecologic Oncology Institution: Lehigh Valley Health Network Member since: 2016 Three years ago, Richard ‘Rick’ Boulay, MD, Chief of Gynecologic Oncology at Lehigh Valley Health Network, walked onto the stage at TEDx Lehigh River and confronted his audience...
Platinum Study Finds High Risk of Metabolic Syndrome in Testicular Cancer Survivors
A multicenter study of North American testicular cancer survivors treated with platinum-based chemotherapy has found a high prevalence of metabolic syndrome, a cluster of cardiovascular risk factors that doubles the risk of cardiovascular disease.1 According to the results of this trial,...
Pacritinib Reduces Spleen Volume in Myelofibrosis
The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 inhibitor pacritinib achieved a significant reduction in spleen volume compared with best available...
Cleveland Clinic Opens New Taussig Cancer Center
The new Cleveland Clinic Taussig Cancer Center began welcoming patients on March 6, 2017. The 377,000 square-foot facility houses all outpatient cancer treatment services in one location, with the center’s team of medical and radiation oncologists, surgeons, nurses, genetic counselors, social...
CAR T-Cell Therapy Emerging in Multiple Myeloma
For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven...
Fox Chase–Temple University Hospital Bone Marrow Transplant Program Awarded FACT Accreditation
The Fox Chase–Temple University Hospital Bone Marrow Transplant Program has received internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center. By demonstrating compliance with the FACT-JACIE...
Study Finds No Evidence of Cytomegalovirus in Glioblastoma and Other High-Grade Gliomas
In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins said they have found no evidence of cytomegalovirus (CMV) infection and concluded that a link between the two diseases, as claimed by earlier reports, likely does not exist. A ...
Phase II Trial Evaluates New Gene Therapy for Non–Muscle Invasive Bladder Cancer After BCG
A novel approach using intravesical gene therapy showed promising activity in a phase II trial that enrolled patients with bacillus Calmette-Guérin (BCG)-refractory or -relapsed nonmuscle invasive bladder cancer.1 The rate of high-grade relapse-free survival at 12 months was 35% in patients treated ...
ASCO Quality Care 2017: Reducing Overuse of Colony-Stimulating Factors in Febrile Neutropenia Without Compromising Patient Safety
In a retrospective cohort study, Adeboyeje et al found that a utilization management tool that makes real-time care recommendations can help reduce overuse of substances that assist the bone marrow in producing blood cells, called colony-stimulating factors, in attempts to prevent fevers in...
Can Histone Deacetylase Inhibitors Reverse Resistance to Angiogenesis Inhibitors?
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al found evidence that the histone deacetylase (HDAC) inhibitor abexinostat may act to reverse resistance to the vascular endothelial growth factor (VEGF) inhibitor pazopanib (Votrient) via epigenetic modulation of VEGF in ...
Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker
Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, a research team from The University of Texas MD Anderson Cancer Center reported in a study by Balasenthil et al in the ...
Poor Diet During Adolescence/Early Adulthood and Risk for Premenopausal Breast Cancer
Although adolescence is a highly susceptible time for mammary carcinogenesis, few prospective studies have examined the role of adolescent diet and breast cancer risk. Now, a study investigating the association of an adolescent and early adulthood dietary pattern that promotes chronic inflammation...
2017 Oncology Meetings
MARCH 2017 ASCO Oncology Practice ConferenceMarch 2 • Orlando, FloridaFor more information: www.asco.org/meetings/symposia-conferences/asco-oncology-practice-conference 23rd Annual Blood-Brain Barrier Consortium Meeting March 2-4 • Stevenson, WashingtonFor more information:...
Circulating Tumor DNA as a Prognostic Marker in Pancreatic Cancer
Translational research in pancreatic adenocarcinoma has been limited by the difficulty of obtaining sufficient quality and quantity tumor tissue from patients. A study by Pietrasz et al assessing the feasibility and prognostic value of circulating tumor DNA (ctDNA) in pancreatic adenocarcinoma has...
Continued Reduction in Cancer Mortality Requires Increasing Healthy Behaviors and Removing Inequities in Care
Many news reports about the latest cancer statistics released by the American Cancer Society (ACS) have focused on the 25% reduction in cancer mortality since 1991. Several reports quoted ACS Chief Medical Officer Otis W. Brawley, MD, FACP, who said in a statement1 announcing the publication of...
Bright Future for Osimertinib in EGFR T790M–Positive Lung Cancer
The AURA3 study—reported by Mok and colleagues and reviewed in this issue of The ASCO Post—confirms the dramatic activity of osimertinib (Tagrisso) in patients with advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC) and acquired resistance to prior EGFR...
Study Finds Children, Parents Overreport Adherence to Leukemia Treatment
New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in...
FDA Approves Lenalidomide as Maintenance Therapy for Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
On February 22, the U.S. Food and Drug Administration (FDA) expanded the existing indication for lenalidomide (Revlimid) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant. The expanded indication makes...
Chinese Trial Adds Utidelone to Capecitabine in Heavily Pretreated Patients With Metastatic Breast Cancer
In a Chinese phase III trial reported in The Lancet Oncology, Zhang et al found that adding the epothilone analog utidelone to capecitabine prolonged progression-free survival in women with heavily pretreated metastatic breast cancer refractory to both anthracycline and taxane treatment. Study...
Myeloablative vs Reduced-Intensity HCT for Acute Myeloid Leukemia and Myelodysplastic Syndromes
In a phase III trial reported in the Journal of Clinical Oncology, Scott et al found that myeloablative conditioning for allogeneic hematopoietic cell transplantation was associated with a reduced risk of relapse and a nonsignificant overall survival advantage vs reduced-intensity conditioning in...
Southern Surgical Association Annual Meeting: Isolated Limb Infusion for Extremity Sarcoma May Preserve Limbs
Patients with advanced malignant soft-tissue sarcoma of the extremities have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these...
2017 ASH-AMFDP Scholars to Study Basic Insights in Blood Cancer Development
The American Society of Hematology (ASH) announced that Justin Taylor, MD, and Roger Belizaire, MD, PhD, have been selected to participate in the American Society of Hematology–Harold Amos Medical Faculty Development Program (ASH-AMFDP). Designed to increase the number of underrepresented...
FDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma
On January 19, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica) for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication based...
New Data on Prognostic Factors, Disease Detection, Drug Toxicities, and Treatment Adherence Presented at SABCS
The San Antonio Breast Cancer Symposium (SABCS) offers state-of-the-art information on all aspects of breast cancer biology, diagnosis, and treatment, drawing an international audience of more than 7,500 physicians, researchers, and other health-care professionals from over 90 countries. Through...
Managing Toxicities Associated With Immunotherapy for Lung Cancer
Understanding, anticipating, and managing the toxicities associated with immunotherapies for lung cancer are key to steps to safely using and achieving the most benefit from these new agents, according to Beth Eaby-Sandy, MSN, CRNP, OCN, a nurse practitioner at the University of Pennsylvania’s...
Early Biomarker Algorithm May Predict Graft-vs-Host Disease Occurrence
Researchers at Mount Sinai Health System have discovered a way to predict whether patients with blood cancer who received a bone marrow transplant will develop graft-vs-host disease, according to a study published by Hartwell et al in JCI (The Journal of Clinical...
Study Finds Mutations in Myelodysplastic Syndrome Linked to Poorer Outcome After Stem Cell Transplantation
In a study reported in The New England Journal of Medicine, Lindsley et al found that a number of mutations present in patients with myelodysplastic syndrome (MDS) were associated with poorer clinical outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Study Details The study ...
Combination of Alisertib and HSV1716 Shows Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor and Neuroblastoma Models
Two investigational agents, the aurora A kinase inhibitor alisertib and a virus derived from HSV-1 (HSV1716), have shown antitumor efficacy in early clinical trials as monotherapies. A new study published by Currier et al in Oncotarget, however, demonstrates that the combined usage...
Disease Symptoms Are the Most Frequent Indicators of Recurrence in Patients With Stage II Melanoma
Recurrences of early-stage (stage II) melanoma are more often detected by patients and their physicians than by routine imaging tests, according to study results published by Berger et al in the Journal of the American College of Surgeons. “We are most concerned about patients who have stage ...
Intermittent Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
In a phase II trial reported in The Lancet Oncology, Dréno et al found that two long-term intermittent vismodegib (Erivedge) dosing regimens provided a similar reduction in the number of clinically significant basal cell carcinomas among patients with multiple lesions. Study Details In the ...
2017 GU Cancers Symposium: Blood Test Uncovers Potential New Treatment Targets in Advanced Prostate Cancer
Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets. Using a commercially available “liquid biopsy” test in patients with advanced prostate cancer, researchers found a number of genetic changes in cell-free, circulating...
Children, Parents Overreport Leukemia Treatment Adherence
New research suggests that young patients with acute lymphocytic leukemia (ALL) and their parents are likely to report to their physician that they took more of their anticancer medication than they actually did. The study, published by Landier et al in Blood, found that 84% of patients with ALL...
Postinduction MRD Predicts Outcome From Transplantation in NPM1-Mutant AML
In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). Nicolas...
I Plan to Live Long Enough to Be Cured of Multiple Myeloma
Like many other patients diagnosed with multiple myeloma, I didn’t know I had the cancer until I broke a bone. I had felt a twinge of pain on my left side when I hoisted a bucket of baseballs over my left shoulder after participating in a baseball tournament in the spring of 2011, but there was...
Kerry and Simone Vickar Family Foundation Commits $2 Million for Levine Cancer Institute Hematologic Oncology Chair
Carolinas HealthCare System has announced a $2 million commitment from the Kerry and Simone Vickar Family Foundation in support of academic and research efforts at the Levine Cancer Institute in Charlotte, North Carolina. The funds will be designated to establish an endowed chair in their name: The ...
2017 Oncology Meetings
FEBRUARY ASCO-SITC Clinical Immuno-Oncology SymposiumFebruary 23-25 • Orlando, Florida For more information: http://immunosym.org FACTOR (Funding, Awareness, Collaboration, Trials, Osteosarcoma Research) Miami Conference 2017February 24-25 • Coral Gables, Florida For more information:...
Telotristat Ethyl: A Novel Therapy for Carcinoid Syndrome—Not a Panacea but a Step in the Right Direction
The multihumoral manifestations of neuroendocrine tumors include diarrhea, cutaneous flushing, wheezing, and right-sided valvular heart disease.1 Serotonin, a biogenic amine and product of tryptophan metabolism,2 mediates several of these symptoms.3,4 Diarrhea is a cardinal and often disabling...
Liquid Biopsies Show Promise in Diffuse Large B-Cell Lymphoma
Technologic advances for detecting and analyzing cell-free circulating tumor DNA (ctDNA) from peripheral blood offer a precision method for monitoring diffuse large B-cell lymphoma (DLBCL). Although most patients with DLBCL are cured with initial therapy, those who are not cured have a poor...
On the Horizon: New Tools for Prostate Cancer
The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors in the treatment of prostate cancer. Not all of these advances are currently clinically actionable, but all have the potential to change clinical...
Early Success Reported With Two New Agents for High-Risk Myelodysplastic Syndromes
At the 2016 American Society for Hematology (ASH) Annual Meeting & Exposition, researchers reported early success with two new experimental agents for high-risk myelodysplastic syndromes—enasidenib (also known as AG-221), a potent oral inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme,...
The Cost of a Patient’s Last Ride
It was a call from a referring physician who wanted the patient to be transferred to our major academic center. The patient had a history of a lethal malignancy in a very advanced stage. The patient was already outside the bell curve, for she had survived far longer than expected for a malignancy...
ASH/AACR/AACI/ASTRO/ASPHO/Lungevity Foundation Statement on Administration's Executive Order
Today, the American Society of Hematology, the American Association for Cancer Research, the Association of American Cancer Institutes, the American Society for Radiation Oncology, the American Society of Pediatric Hematology/Oncology, and the LUNGevity Foundation issued a statement on the...
